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Abstract: The nuclear receptor PPARα is associated with reducing adiposity, especially in the liver,
where it transactivates genes for β-oxidation. Contrarily, the function of PPARα in extrahepatic tissues
is less known. Therefore, we established the first adipose-specific PPARα knockout (PparaFatKO )
mice to determine the signaling position of PPARα in adipose tissue expansion that occurs during
the development of obesity. To assess the function of PPARα in adiposity, female and male mice
were placed on a high-fat diet (HFD) or normal chow for 30 weeks. Only the male PparaFatKO
animals had significantly more adiposity in the inguinal white adipose tissue (iWAT) and brown
adipose tissue (BAT) with HFD, compared to control littermates. No changes in adiposity were
observed in female mice compared to control littermates. In the males, the loss of PPARα signaling in
adipocytes caused significantly higher cholesterol esters, activation of the transcription factor sterol
regulatory element-binding protein-1 (SREBP-1), and a shift in macrophage polarity from M2 to M1
macrophages. We found that the loss of adipocyte PPARα caused significantly higher expression of
the Per-Arnt-Sim kinase (PASK), a kinase that activates SREBP-1. The hyperactivity of the PASK–
SREBP-1 axis significantly increased the lipogenesis proteins fatty acid synthase (FAS) and stearoylCoenzyme A desaturase 1 (SCD1) and raised the expression of genes for cholesterol metabolism
(Scarb1, Abcg1, and Abca1). The loss of adipocyte PPARα increased Nos2 in the males, an M1
macrophage marker indicating that the population of macrophages had changed to proinflammatory.
Our results demonstrate the first adipose-specific actions for PPARα in protecting against lipogenesis,
inflammation, and cholesterol ester accumulation that leads to adipocyte tissue expansion in obesity.
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1. Introduction
Despite it being over three decades since the discovery of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) [1], its role in extrahepatic tissues remains
ambiguous. PPARα ligands, such as fibrates or the newly discovered endogenous ligand,
bilirubin [2–5], are beneficial in reducing plasma triglyceride levels [6,7] and possibly in
lowering plasma apolipoprotein B100 (ApoB100) [8,9], which both originate from the liver.
While most studies have revealed the primary function of PPARα is in the liver, others
have shown that the nuclear receptor also regulates body weight and adiposity [10–13].
However, most anti-adiposity mechanisms have been supported in studies using PPARα
ligands that elicit whole-body responses or global PPARα knockout (KO) animals. The
explicit tissue-specific mechanisms are not yet clearly understood. Mice with a global
PPARα knockout (Ppara−/− ) were generated over two decades ago [14], and many studies have utilized these animals for understanding signaling mechanisms. However, the
results depend on the background of the Ppara−/− mice; for example, studies of Sv/129 or
C57BL/6N genetic backgrounds in these mice showed discrepancies in the development of
adiposity, or that they acquire obesity in a sexually dimorphic fashion [15–17].
Potential inconsistencies in the former studies most likely emanated from the use of
the global PPARα knockout (Pparα−/− ) mice with excised exon 8 [14], which removes helix
12 of the ligand-binding domain (LBD) [18]. These animals were later found to have a
smaller truncated PPARα isoform that contains the DNA-binding domain (DBD) [18], which
might be hyperactive and cause some of the divergences observed in the previous studies.
De Souza et al., compared the global PPARα KO mice with Ppara siRNA knockdown
in C57/BL6 mice. They found that siRNA suppression of PPARα in mice provided a
variance in responses compared to global PPARα KO animals [19]. Nevertheless, they
found a high-transcriptional concordance in the magnitude and direction between Ppara
siRNA-treated mice and global PPARα KO mice aligned using genome-wide transcriptional
profiling [19]. However, these comparisons were to the WT mice treated with the PPARα
ligand fenofibrate, in which the global PPARα KO mice do not contain helix 12 of the
LBD, and for this reason, do not have ligand responses. Hence, the smaller truncated form
without the LBD might interfere with PPARα signaling that is not visible when comparing
ligand responses, which might have caused variances in the previously published works.
A consensus in past studies supports that PPARα controls hormones that regulate
adiposity, especially in the liver, such as PPARα-induced fibroblast growth factor 21
(FGF21) [20], a well-established anti-obesity and anti-diabetic hepatokine hormone. Together, knowing that PPARα controls hepatokines that may also control adiposity and that
global PPARα KO mice have a smaller truncated form drives the need for more studies
utilizing PPARα-tissue-specific KO animals with both isoforms targeted. Recently, PPARα
floxed (Pparafl/fl ) mice that excise exon 4 to remove all PPARα isoforms were generated and
used to develop hepatocyte-specific PPARα KO (PparaHepKO ) animals that were shown to
have hepatic steatosis on a normal-chow diet [21,22] as well as significantly worsened lipid
accumulation, hepatic inflammation, and hyperlipidemia on a high-fat diet [21]. Using
different PPARα floxed mice from the Gonzalez lab that excises exon 5 [23], Brocker et al.
generated hepatocyte-specific PPARα KO (Ppara∆Hep ) and macrophage-specific PPARα KO
(Ppara∆mac ) animals. Interestingly, they found that the PPARα ligand WY 14,643 controls
body weight loss via the liver as the Ppara∆hep did not lose weight with the treatment with
this compound compared to mice with intact hepatic PPARα [23]. Other work by Wang
et al. using the same PPARα floxed mice with exon 5 excised, showed that cardiomyocyte
PPARα is essential for energy metabolism and extracellular matrix homeostasis during
pressure-overload-induced cardiac remodeling [24]. Their bioenergetic analyses showed
that basal and maximal oxygen consumption rates (OCR) and ATP production significantly
increased in hypertrophic Pparafl/fl hearts, and was reduced in Ppara∆CM hearts. However,
these studies did not use a high-fat diet challenge to determine whether the tissue-specific
effects of PPARα or its ligand-induced actions were altered. For instance, Gordon et al.,
showed that bilirubin activated PPARα in obese animals to increase the mitochondrial
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2.2. Body Composition
The changes in body composition were assessed as we have previously described [2,5,21,27,30].
In brief, the body composition was quantitated at 4-week intervals throughout the study
using magnetic resonance imaging (EchoMRI-900TM, Echo Medical System, Houston, TX,
USA). Conscious mice were placed in a thin-walled plastic cylinder and briefly submitted
to a low-intensity electromagnetic field where fat mass, lean mass, free water, and total
water were measured.
2.3. Analysis of Plasma Lipids and Metabolites
Nuclear magnetic resonance (NMR) spectroscopy experiments quantitating plasma
lipids and metabolites were as previously described [7,21]. In brief, we used a 14.0 T Bruker
magnet equipped with a Bruker AV-III console operating at 600.13 MHz. Experiment
conditions included: sample temperature of 310 K, 96 k data points, 30 ppm sweep width,
a recycle delay of 4 s, a mixing time of 150 ms, and 32 scans. All spectra were acquired
in 3 mm NMR tubes using a Bruker 5 mm QCI cryogenically cooled NMR probe. Plasma
samples were prepared and analyzed according to the Bruker In-Vitro Diagnostics research
(IVDr) protocol. Sample preparation consisted of combining 50 uL of plasma with 150 uL of
the buffer supplied by Bruker Biospin specifically for the IVDr protocol. For 1D 1 H NMR,
data was acquired using the 1D-NOE experiment, which filters NMR signals associated
with broad line widths. Lipoprotein subclass analysis was performed using regression
analysis of the NMR data, which is done automatically as part of the IVDr platform as
previously described.
2.4. Lipidomics
Lipids were extracted using acidified organic solvents as described previously [31–33].
Lipid class-specific internal standards (Avanti Polar Lipids, Alabaster, AL, USA) were
added at the start of the extraction. Dried lipid residues were reconstituted for analysis.
The instrument system was a Shimadzu Nexera UHPLC system coupled with an AB
Sciex 6500+ Q-Trap linear ion trap/triple quadrupole mass spectrometer. Lipids were
separated by HILIC chromatography using a Phenomenex Luna Silica Column with a
guard column of the same material and detected in multiple reaction monitoring modes
using literature method adaptations. In brief, this approach takes advantage of the ability
of HILIC chromatography to separate the major classes of glycero and sphingo lipids which
then enables the use of time-scheduled measurements of multiple lipid species within each
class. The use of weakly alkaline solvents (pH 8.0) enhances the detection of anionic lipids
in negative-ionization mode. Most lipids are monitored as their precursor molecular ions,
but in some cases, lipids were monitored as ammoniated adducts. The high sensitivity
and speed of the instrument allow for the accurate integration of chromatographic peaks.
The method used was optimized using a standard mouse-liver lipid extract to identify
retention times and exclude lipid species that are present at low levels and/or not detected
consistently. The final optimized method was used to analyze lipids in experimental
samples, with data collected for three technical replicates of each sample. Data were
analyzed using AB Sciex MultiQuant software (Framingham, MA, USA) for peak finding
and integration. The raw peak areas were normalized for recovery of the appropriate
internal standards. Lipids species with coefficients of variation of greater than 20% were
excluded from the final report.
2.5. Quantitative Real-Time PCR Analysis
Total RNA was harvested from Pparafl/fl and PparaFatKO mice by lysing samples
using a Qiagen Tissue Lyser LT (Qiagen, Hilden, Germany) and then extraction by a
5-Prime PerfectPure RNA Tissue Kit (Fisher Scientific Company, LLC, Waltham, MA, USA).
Total RNA was read on a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific,
Wilmington, DE, USA), and cDNA was synthesized using a High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Waltham, MA, USA). PCR amplification of the
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cDNA was performed by quantitative real-time PCR using TrueAmp SYBR Green qPCR
SuperMix (Alkali Scientific, Fort Lauderdale, FL, USA) for gene-specific primers (Table 1)
and as previously described [5,20,27,30,34,35]. The thermocycling protocol consisted of
5 min at 95 ◦ C, 40 cycles of 15 sec at 95 ◦ C, and 30 sec at 60 ◦ C, finished with a melting
curve ranging from 60 to 95 ◦ C to allow distinction of specific products. Normalization was
performed in separate reactions with primers to 36B4.
Table 1. Primer sequences used in this study.
Gene

Forward Primer

Reverse Primer

36B4

CACTCTCGCTTTCTGGAGGG

ACGCGCTTGTACCCATTGAT

Cre

GAACCTGATGGACATGTTCAGG

AGTGCGTTCGAACGCTAGAGCCTGT

Ppara

AGAAGTTGCAGGAGGGGATT

TTGAAGGAGCTTTGGGAAGA

Pask

GAATCCGACTGAGACTTGCG

TAACTAACACTCGCCGCCAC

Scarb1

CCCCAGGTTCTTCACTACGC

TCCTTATCCTGGGAGCCCTT

Abca1

GGCAATGAGTGTGCCAGAGTTA

TAGTCACATGTGGCACCGTTTT

Abcg1

TCCCCACCTGTAAGTAATTGCA

TCGGACCCTTATCATTCTCTACAGA

Adgre1

GCCCAGGAGTGGAATGTCAA

GCAGACTGAGTTAGGACCACA

Nos2

CCTTGGTGAAGGGACTGAGC

TCCGTGGAGTGAACAAGACC

Fizz1

GGGATGACTGCTACTGGGTG

TCAACGAGTAAGCACAGGCA

Arg1

AAGAGTCAGTGTGGTGCTGG

TGGTTGTCAGGGGAGTGTTG

Tnfa

GACTCAAATGGGCTTTCCGA

TCCAGCCTCATTCTGAGACAGAG

2.6. Gel Electrophoresis and Western Blotting
Mouse tissues were flash-frozen in liquid nitrogen during harvesting and stored at
−80 ◦ C. For gel electrophoresis, 50–100 mg of cut tissue was then resuspended in 3 volumes
of M-PER Mammalian Protein Extraction Reagent (ThermoFisher Scientific, Waltham, MA,
USA, Cat no: 78501) plus 10% protease inhibitor cocktail (Sigma P2714-1BTL, Sigma Aldrich,
St. Louis, MO, USA) and Halt phosphatase inhibitor cocktail (Fisher PI78420, Thermo Fisher,
Waltham, MA, USA), and then incubated on ice for 30 min. The samples were lysed using
a Qiagen Tissue Lyser LT (Qiagen, Hilden, Germany) and then centrifuged at 100,000× g
at 4 ◦ C. Protein samples were resolved by SDS polyacrylamide gel electrophoresis and
electrophoretically transferred to Immobilon-FL membranes. Membranes were blocked
at room temperature for 1 h in the LI-COR Intercept Blocking Buffer (LI-COR Biosciences,
Lincoln, NE, USA, Cat no: 927-60001). Subsequently, the membranes were incubated
overnight at 4 ◦ C with the following antibodies: SREBP-1 (Santa Cruz Biotechnology,
Dallas, TX, USA, Cat no: sc-367; 1:250 dilution in TBS), FAS (Cell Signaling, Danvers, MA,
USA, Cat no: 3180s; 1:1000 dilution in TBS), SCD1 (Cell Signaling, Danvers, MA, USA, Cat
no: 2794; 1:500 dilution in TBS), RPLP0 (36B4) (ThermoFisher Scientific, Waltham, MA,
USA, Cat no: 11290-2-AP; 1:1000 dilution in TBS), or heat shock protein 90 (HSP90) (Santa
Cruz Biotechnology, Dallas, TX, USA, Cat no: sc-13119; 1:10,000 dilution in TBS). After three
washes in TBS + 0.1% Tween 20, the membrane was incubated with an infrared anti-rabbit
(IRDye 800, green) or anti-mouse (IRDye 680, red) secondary antibody labeled with IRDye
infrared dye (LI-COR Biosciences, Lincoln, NE, USA) (1:10,000 dilution in TBS) for 2 h at
4 ◦ C. Immunoreactivity was visualized and quantified by infrared scanning in the Odyssey
system (LI-COR Biosciences, Lincoln, NE, USA).
2.7. Statistical Analysis
Data were analyzed with Prism 9 (GraphPad Software, San Diego, CA, USA) using
analysis of variance combined with Tukey’s post-hoc test to compare pairs of group means
or unpaired t-tests. Results are expressed as mean ± SEM. Additionally, a one-way ANOVA
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with a least significant difference post-hoc test was used to compare mean values between
multiple groups, and a two-tailed and a two-way ANOVA was utilized in multiple comparisons, followed by the Bonferroni post-hoc analysis to identify interactions. p values of
0.05 or smaller were considered statistically significant.
3. Results
3.1. Adiposity in Adipocyte-Specific PPARα Knockout and Control Littermate Mice on High-Fat
and Regular-Chow Diets
While many studies have supported a role for PPARα in reducing body weight and
possibly adiposity, the definitive function of PPARα in adipose tissue has not been resolved.
Therefore, we wanted to determine the function of PPARα explicitly in adipocytes and
whether an adipocyte-specific loss of PPARα (PparaFatKO ) causes metabolic disturbances or
adiposity. Here, we generated mice using Pparafl/fl described in [21,22] crossed with mice
containing an adiponectin-Cre (Adipoq-Cre) to establish an adipocyte-specific KO (Figure 1),
as we have previously described [36]. Analysis of the tissue distribution of PPARα in
Pparafl/fl and PparaFatKO indicated that expression was reduced 89.5% in males and 94.5%
in females in inguinal white adipose tissue (iWAT) (also referred to as subcutaneous fat)
and to a lesser extent in brown adipose tissue (BAT) (data not shown). Very low PPARα
expression was observed in epididymal white adipose tissue (eWAT) for males and females;
this same observation has been reported previously [37]. To determine whether the absence
of PPARα would impact adiposity and fat-pad size, we fed the PparaFatKO and littermate
control (Pparafl/fl ) mice a normal-chow diet (NCD) or high-fat diet (HFD) for 30 weeks. We
found that the male PparaFatKO mice compared to Pparafl/fl on an HFD had significantly
higher iWAT (two-way ANOVA, p = 0.0091) and BAT (two-way ANOVA, p = 0.0031), but
no significant differences in body weight (two-way ANOVA, p = 0.0840), total fat (twoway ANOVA, p = 0.0982), or eWAT (two-way ANOVA, p = 0.9991) between the groups
(Figure 2A). Also, there were no differences between heart or liver weights for NCD or HFD
for the males (data not shown). The female PparaFatKO compared to the female Pparafl/fl
mice on NCD or HFD had no significant differences in body weights, fat mass, iWAT, eWAT,
BAT (Figure 2B), heart, or liver weights (data not shown). It should be noted that there
was a trend for these measurements to be higher for males in the HFD group for body
weight and total fat between the PparaFatKO and Pparafl/fl mice but lower for females for all
HFD groups. However, these observations were not significant. The eWAT was larger by
HFD feeding in the females for both genotypes, but no change was observed in the males.
This may have been due to the intrinsically low levels of PPARα in eWAT [37]. Mice on
an HFD [38] or those that are genetically ob/ob obese [20,38] have been demonstrated to
have reduced PPARα expression in adipose and liver tissues. When comparing the HFD to
NCD in the Pparafl/fl animals, the PPARα expression in iWAT was reduced by 94.65% in
males and 88.46% in females by the HFD (data not shown). In comparing sex differences
for PPARα levels, the expression of PPARα was 90.8% lower in the females compared to
the males for the iWAT of the Pparafl/fl mice on normal chow (Figure 1). Therefore, we
deduce that there is a sexual dimorphism for PPARα in adipose tissue. Male mice with
an adipocyte-specific loss of PPARα (PparaFatKO ) have increased adiposity in fat depots
iWAT and BAT, but this was not observed in females. The latter is presumably related
to estrogen. Previous work has shown that estrogen suppresses PPARα transcriptional
activity [11,39–41] and controls adipocyte size [42]. This indicate that estrogen in females
offers a protective factor in reducing adiposity independent of PPARα adiposity-reducing
mechanisms.
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PPARα controls β-oxidation to produce the major fatty acid metabolite and ketone,
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β-hydroxybutyrate (BHOB), which is released from the liver into the blood [43]. There were
no significant differences for the PparaFatKO and Pparafl/fl mice on HFD or NCD for plasma
levels of BHOB (measured as 3-hydroxybutyric acid, the yellow section on the pie graph)
(Figure 4A–F). This result could be anticipated as BHOB comes primarily from the liver [44].
The results in females show that pyruvic acid was significantly lower in the PparaFatKO
HFD-fed group compared to littermate control mice fed the same diet (Figure 4F). These
results might be related to PPARα regulation of pyruvate dehydrogenase activity in adipose
tissue of females, as it is known to regulate this activity [45]. The metabolite data essentially
show no differences among the groups or genotypes.
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PPARα controls β-oxidation to produce the major fatty acid metabolite and ketone,
β-hydroxybutyrate (BHOB), which is released from the liver into the blood [43]. There
were no significant differences for the PparaFatKO and Pparafl/fl mice on HFD or NCD for
plasma levels of BHOB (measured as 3-hydroxybutyric acid, the yellow section on the pie
graph) (Figure 4A–F). This result could be anticipated as BHOB comes primarily from the
liver [44]. The results in females show that pyruvic acid was significantly lower in the
PparaFatKO HFD-fed group compared to littermate control mice fed the same diet (Figure
4F). These results might be related to PPARα regulation of pyruvate dehydrogenase activity in adipose tissue of females, as it is known to regulate this activity [45]. The metabolite data essentially show no differences among the groups or genotypes.
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groups for male or female mice on NCD or HFD for total cholesterol (TPCH), LDL
(LDCH), HDL (HDCH), VLDL (VLPN), or LDL particle number (LDPN) (Figure 5A,B).
However, it should be noted that most of these lipids were significantly changed between

Figure 4. Plasma metabolites in PparaFatKO and Pparafl/fl mice fed high-fat or normal-chow diets. Pie
and bar graphs of plasma amino acids in male (A–C) and female (D–F) PparaFatKO and Pparafl/fl mice
on high-fat (HFD) or normal-chow (NCD) diets. **, p < 0.01 (vs. Pparafl/fl HFD) (male n = 8 NCD and
n = 7 HFD, Pparafl/fl; female n = 6 NCD and n = 4 HFD, Pparafl/fl; male n = 8 NCD and n = 8 HFD,
PparaHepKO; female n = 6 NCD and n = 4 HFD, PparaHepKO).
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Figure 5. Plasma total cholesterol, VLDL, and LDL particle numbers in Pparafl/fl and PparaFatKO mice.
Total plasma cholesterol (TPCH), LDL cholesterol (LDCH), HDL cholesterol (HDCH), VLDL particle
number (VLPN), and LDL particle number (LDPN) as measured by NMR spectroscopy in plasma
of male (A) and female (B) PparaFatKO and Pparafl/fl mice on high-fat (HFD) or normal-chow (NCD)
diets. (male n = 8 NCD and n = 7 HFD, Pparafl/fl ; female n = 6 NCD and n = 4 HFD, Pparafl/fl ; male
n = 8 NCD and n = 8 HFD, PparaHepKO ; female n = 6 NCD and n = 4 HFD, PparaHepKO ).

3.3. Lipidomics and Signaling in Adipocyte-Specific PPARα Knockout and Littermate
Control Mice
The above results indicate that adipocyte PPARα does not regulate plasma levels
of amino acids, metabolites, or cholesterol, or lipoprotein metabolism. Therefore, we
wanted to specifically investigate the adipose tissue responses in iWAT as this was significantly different for the male PparaFatKO on HFD compared to littermate controls on the
same diet. Using iWAT from all groups of mice, we performed lipidomics using liquid
chromatography–mass spectrophotometry (LC mass spec). Volcano-plot analysis of the
lipidomics data showed that male PparaFatKO had more significant responses, as related to
the higher values on the y-axis for the HFD vs. NCD when compared to Pparafl/fl littermates
(Figure 6A). The female mice did not show similar significant differences when comparing
the y- axis for the PparaFatKO to the Pparafl/fl (Figure 6B). Next, we wanted to compare
the volcano plots in the PparaFatKO to the Pparafl/fl for males and females. To determine
the lipid species that were most changed, we quantitated the differences between the diet
groups and PparaFatKO versus Pparafl/fl mice (KO(HFD/NCD)–WT(HFD/NCD)). We also
wanted to determine if there were any clusters of specific lipids visible that might indicate
signaling pathways that control their generation. This analysis showed that the PparaFatKO
mice had several triacylglycerides (TAGs) that were higher in the males (Figure 6C,D). The
specific TAGs that were raised in the male PparaFatKO mice were TAG 42:1/FA18:1, TAG
44:1/FA18:1, TAG 44:1/FA16:0, TAG 56:5/FA20:3; TAG 46:0/FA18:0, and TAG 42:1/FA16:0.
The female PparaFatKO mice did not show similar patterns, and the changes were overall
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very low (Figure 6E,F). The male mice had a cluster showing that cholesterol esters were
11 of 21
elevated as indicated by blue arrows (Figure 6C), but this was not observed at the same
level in females (Figure 6E).

fl/fl
FatKO
fl/fl
FatKO
Figure 6.
and
Ppara
mice.mice.
Lipidomics
of iWAT
usingusing
liquidliquid
chroFigure
6. Lipidomics
Lipidomicsof
ofiWAT
iWATininPpara
Ppara
and
Ppara
Lipidomics
of iWAT
matography–mass
spectrophotometry
(LC
mass
spec)
represented
as
volcano-plot
analysis
in
male
chromatography–mass spectrophotometry (LC mass spec) represented as volcano-plot analysis
in
FatKO and Pparafl/fl mice on high-fat (HFD) or normal-chow (NCD) diets. Or(A)
and
female
(B)
Ppara
FatKO
fl/fl
male (A) and female (B) Ppara
and Ppara
mice on high-fat (HFD) or normal-chow (NCD)
ganization of the top 50 and bottom 50 most-changed lipids in male (C,D) and female (E,F) PparaFatKO
diets. Organization
of the top 50 and bottom 50 most-changed lipids in male (C,D) and female (E,F)
and Pparafl/fl mice. The
arrows identify cholesterol esters. (male n = 7 NCD and n = 8 HFD,
fl/flblue
PparaFatKO
and
Ppara
mice. The blue arrows identify cholesterol esters. (male n = 7 NCD and
Pparafl/fl; female n = 6 NCD and n = 4 HFD, Pparafl/fl; male n = 7 NCD and n = 8 HFD, PparaHepKO;
fl/fl ; female n = 6 NCD and n = 4 HFD, Pparafl/fl ; male n = 7 NCD and n = 8 HFD,
n
= 8 HFD,
female
n = 6Ppara
NCD and
n = 4 HFD, PparaHepKO).
HepKO
Ppara
; female n = 6 NCD and n = 4 HFD, PparaHepKO ).

These results indicate that intracellular signaling in iWAT could be changed specifiThese results indicate that intracellular signaling in iWAT could be changed specifically
cally in males, but not females, as this causes higher lipids and cholesterol esters. Therein males, but not females, as this causes higher lipids and cholesterol esters. Therefore, we
fore, we measured the master regulator of an intracellular cholesterol signaling molecule,
measured the master regulator of an intracellular cholesterol signaling molecule, SREBP-1,
SREBP-1, and whether the mature form, which is the only form that can function as a
and whether the mature form, which is the only form that
can function as a transcription
transcription factor [47], was more present in the PparaFatKO male mice on HFD. We found
factor [47], was more present in the PparaFatKO male mice on HFD. We found that SREBP-1
that SREBP-1 mRNA was unchanged (data not shown), but the mature form of the SREBPmRNA was unchanged (data not shown), but theFatKO
mature form of the SREBP-1 protein was
1 protein was significantly higher
the Ppara
male mice on HFD (Figure 7A). The
FatKOin
significantly higher
in
the
Ppara
male
mice
on
HFD (Figure 7A). The female PparaFatKO
female PparaFatKO mice on HFD did not have a high level of the mature SREBP1 form (Figmice on HFD did not have a high level of the mature SREBP1 form (Figure 7B). The
ure 7B). The
SREBP-1 transcription
factor
hastobeen
shown
to cause lipid by
accumulation
by
SREBP-1
transcription
factor has been
shown
cause
lipid accumulation
regulating the
regulating
the
expression
of
fatty
acid
synthase
(FAS)
and
stearoyl-coenzyme
A
desatuexpression of fatty acid synthase (FAS) and stearoyl-coenzyme A desaturase 1 (SCD1) [48].
FatKO and Pparafl/fl male mice
rase 1 (SCD1) [48].
of iWAT
the Ppara
FatKOfrom
fl/fl male
Immunoblotting
of Immunoblotting
iWAT from the Ppara
and Ppara
mice on HFD showed
FatKO
on HFD
that
SCD1
and FAS higher
were significantly
higher
(pFatKO
< 0.01)
in mice
the Ppara
that
SCD1showed
and FAS
were
significantly
(p < 0.01) in the
Ppara
male
on HFD
fl/fl
male mice on
HFD
compared
to the
Ppara
the same
diet
(Figure
The
fl/fl mice
compared
to the
Ppara
on the
samemice
dieton
(Figure
7A).
The
female7A).
mice
onfemale
HFD
mice
on
HFD
showed
no
significant
differences
for
SCD1
or
FAS
expression
(Figure
7B).
showed no significant differences for SCD1 or FAS expression (Figure 7B).

Cells 2022, 11,
10, 4x FOR PEER REVIEW

of 21
20
1211of

fl/fl
fl/fl and PparaFatKO
Figure 7. PASK–SREBP-1
PASK–SREBP-1 signaling
signaling in
iniWAT
iWATofofPpara
Ppara
and Ppara FatKO mice.
mice. Western
Western blotting and
densitometry
of
SREBP-1
and
36B4
as
the
control,
and
stearoyl-coenzyme
A desaturase
1 (SCD1)
densitometry of SREBP-1 and 36B4 as the control, and stearoyl-coenzyme A desaturase
1 (SCD1)
and
fl/fl and Ppara
FatKO
fl/fl
and
fatty
acid
synthase
(FAS)
and
heat
shock
protein-90
(HSP90)
as
control
in
Ppara
fatty acid synthase (FAS) and heat shock protein-90 (HSP90) as control in Ppara
and PparaFatKO on
fl/fl HFD)
on HFD in (A) male and (B) female mice. * p < 0.05, ** p < 0.01, Student-t test (versus Pparafl/fl
HFD in (A) male and (B) female mice. * p < 0.05, ** p < 0.01, Student-t test (versus Ppara
HFD)
(± S.E.M.; male and female, n = 6 for FAS and SCD1 male; n = 4 for SREBP1 for male and female).
(± S.E.M.; male and female, n = 6 for FAS and SCD1 male; n = 4 for SREBP1
for male and female).
Real-time mRNA expression for Pask, Scarb1, Abca1, and Abcg1 in Pparafl/fl
and PparaFatKO on NCD or
fl/fl and PparaFatKO on NCD
Real-time
mRNA
expression
for
Pask,
Scarb1,
Abca1,
and
Abcg1
in
Ppara
HFD in (C) male and (D) female mice. * p < 0.05, two-way ANOVA (versus HFD Pparafl/fl) (male n =
fl/fl
HFDand
in (C)
andPpara
(D) female
mice.
p < 0.05,
ANOVA
(versus
fl/fl; male
7orNCD
n =male
7 HFD,
n = 8* NCD
andtwo-way
n = 8 HFD,
PparaHepKO
). HFD Ppara ) (male
fl/fl
HepKO
n = 7 NCD and n = 7 HFD, Ppara ; male n = 8 NCD and n = 8 HFD, Ppara
).
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lyzed the macrophage marker F480 (Adgre1 gene) and found that there were no statistically significant differences between the four groups for males or females (Figure 8). We
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Investigations have shown that fenofibrate inhibits adipocyte hypertrophy and insulin
resistance by activating adipose PPARα in HFD-induced obese male mice [10,13]. Our
results in males suggest that iWAT and BAT adipose depots express a responsive PPARα,
which is why they were significantly changed. However, no differences in eWAT of
the males were detected. Others have shown that eWAT has almost no expression of
PPARα [37]. Therefore, the changes in iWAT and BAT and no response in eWAT in the
males could be anticipated. Each fat depot has specific actions [51], and sexual dimorphism
has been shown to have differential responses in iWAT and eWAT [52]. As per metabolic
disorders, the iWAT, more commonly referred to in humans as subcutaneous fat, is typically
the most prominent fat depot [51,53]. Expansion of the WAT pads is considered to worsen
obesity-related comorbidities by secreting inflammatory cytokines [54–56]. The primary
function of iWAT is to store triglycerides and free cholesterol [57,58]. The finding that
cholesterol esters were raised in the PparaFatKO male mice on HFD compared to the Pparafl/fl
on the same diet is new and is an unexpected role for PPARα. Fish oil, which activates
PPARα and PPARγ, has been shown to significantly reduce cholesterol esters (0.2+/− fish
oil versus 1.2+/− olive oil) in WAT of Ldlr−/− mice [59]. Interestingly, PPARγ increases
adipocyte cholesterol levels [60]. Inversely, Chinetti et al. showed that activation of
PPARα with different ligands reduced cholesterol esters in macrophages, reducing foam-cell
formation that causes atherosclerosis [61]. The function of PPARα and PPARγ in adiposity
has been considered opposing, as PPARγ regulates adipogenesis and lipogenesis [35,62,63],
while PPARα reduces fat accumulation [5,7,27,30].
The master regulator of cholesterol, SREBP-1, regulates the balance of intracellular fat
levels and lipogenesis [64]. SREBP-1 is increased with adiposity [64] and is a factor that
drives gene transcription of lipogenic genes such as FAS and SCD1 [48,64,65]. We found
that the PparaFatKO male mice on an HFD had more of the mature active form of SREBP-1,
leading to higher expression of target genes such as SCD1 and FAS (Figure 9). The higher
levels of FAS and SCD1 likely caused higher TAGs in the iWAT, as these specific lipids are
known to be produced by SCD1 [66] and FAS [67]. The elevated expression of FAS and
SCD1 was most likely related to PPARα regulation of SREBP-1 and PASK, and a loss of
PPARα caused their activation. In our previously published work, we have shown that
bilirubin-induced PPARα activity suppresses SREBP-1 in the liver of obese mice [27] and
that FAS and SCD1 were also reduced, which lowered adiposity [5,7,27,30]. The finding
that PASK was significantly higher in the PparaFatKO male mice on an HFD compared to
littermate controls on the same diet suggests that PPARα might control PASK levels to
inhibit the PASK–SREBP-1 axis from reducing adiposity.
The PASK KO mice had significantly higher PPARα and heme oxygenase-1 (HO-1)
expression in the liver and increased mitochondrial function [68]. We have shown that
activation of HO-1 in obese mice enhanced PPARα and its target genes and reduced
hepatic lipid accumulation [20]. We have also shown that knockout of BVRA increased
lipid accumulation [26,30,36,69,70], which correlated with reduced PPARα levels and target genes [30,36]. The HO-1–BVRA–bilirubin–PPARα axis most likely antagonizes the
PASK–SREBP-1 signaling. Dongil et al. showed PASK deficiency activated antioxidant
mechanisms in the liver and increased HO-1 and PPARα levels [71]. They also demonstrated that the PASK knockout mice are resistant to dietary-induced obesity, are protected
from glucose intolerance on an HFD, and have significantly lower plasma triglyceride
levels [71]. This was supported by Pérez-García et al., who showed PASK-deficient mice
are protected from metabolic complications [72,73]. They also found that PPARα was
higher in the livers of the PASK knockout mice and that FAS and SCD1 were significantly
lower [72,73]. Hao et al. showed that the PASK KO animals had reduced body weight
on an HFD and significantly fewer liver triglycerides [74]. For this reason, Zhang et al.
identified PASK as an emerging regulator of glucose and lipid metabolism [75]. These
studies indicate that there might be a reciprocal relationship between PPARα and PASK,
and based on our results, it is possible that PPARα directly represses PASK expression.
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However, more studies are needed to determine the molecular mechanism by which PPARα
represses PASK.
The primary function of PPARα has been studied in the liver. Our study, here, on
PPARα in adipocytes showed that BOHB was not changed between the adipocyte-specific
PPARα knockout and floxed mice of both sexes. These results could be anticipated because
this metabolite almost exclusively comes from the liver during fat utilization and burning [43]. BOHB is produced by ketogenesis, which is a series of reactions that lead to the
formation of ketone bodies. PPARα via a transcriptional network mediates ketogenesis
through ACOX1, AMP-activated protein kinase (AMPK), PPARγ coactivator 1α (PGC-1α),
mammalian target of rapamycin (mTOR), and fibroblast growth factor 21 (FGF21) [76].
We have shown that bilirubin-induced PPARα activity in obese mice increased ACOX1
and BOHB inducing β-oxidation and utilization of hepatic lipids, which improved liver
function as measured by a reduction in aspartate aminotransferase (AST) level, a hepatic dysfunction marker, and suppression of liver inflammation [7]. Hence, bilirubin via
activation of PPARα has protective actions and reduces adiposity [77–83].
While total macrophage population marker F480 (Adgre1) was not different between
the groups, iNOS (Nos2) proinflammatory marker was significantly higher. Adipose tissue
expansion in obesity causes a phenotypic switch in macrophage polarization, and iNOS
is a well-established marker for such polarity shift [21,34,84]. Becerril et al. demonstrated
that Nos2 knockout mice do not develop adipose tissue inflammation in leptin-deficient
ob/ob mice [85]. We showed that hepatocyte-specific PPARα KO animals on HFD had
significantly higher hepatic iNOS and worsened inflammation with a polarity shift in
macrophage markers to proinflammatory [21]. Marino et al. also showed that adenoviral
overexpression of the inflammatory factor GRβ reduced PPARα in the liver of mice on
normal chow [34]. GRβ increased iNOS inducing a switch in the immune cell population from anti-inflammatory macrophages to proinflammatory, causing significantly more
liver-fat accumulation [34]. GRβ is the inhibitory GR isotype that suppresses cortisol responsiveness [56,86,87] leading to inflammation [34,56,87–91] and adiposity [34,56]. Hence,
the function of PPARα is to control pathways that increase fat burning, lessening adiposity
and inflammation [2,4,5,27–29].
5. Conclusions
In conclusion, our study and work from others indicate that PPARα responses are
sexually dimorphic and that estrogen may either suppress PPARα expression or inhibit
signaling. Estrogen has anti-adiposity mechanisms that protect females from gaining
as much weight as males on a high-fat diet [42]. The use of PPARα ligands in obese
male mice reduces body weight [2,5,7], which might not be beneficial for females until
after menopause. However, more studies are needed to understand these effects better
in females. We also conclude that adipocytic PPARα does not regulate plasma levels of
cholesterol such as LDL or HDL, but does regulate the intracellular level of cholesterol
esters, as was previously shown in macrophages [61]. The importance of PPARα regulation
of cholesterol esters in adipocytes is unclear, and more studies are needed to elucidate the
function. Our investigation here reflects the first explicit function of PPARα in adipose
tissue, which was shown to be fundamental in regulating the PASK–SREBP-1 axis to control
lipogenesis and FAS and SCD1 expression (Figure 9). The role of PPARα in the regulation of
macrophage polarity and inflammation could be mediated via PASK or vice versa. Future
investigations could reveal whether PPARα directly downregulates PASK, which appears
to be an essential kinase that might induce metabolic dysfunction.

Cells 2022, 11, 4

16 of 20

Author Contributions: T.D.H.J. and D.E.S. conceived the project and designed the experiments. W.W.
provided the animals for the study. D.E.S. performed the animal experiments. Z.A.K. performed
real-time PCR and adipocyte analysis. M.X. performed immunoblotting and analysis. A.J.M. performed the mass spectrometer lipidomics measurements, and Z.A.K. performed the analysis. D.F.S.
performed the plasma metabolite and cholesterol measurements. T.D.H.J., Z.A.K., M.X., F.B.Y., A.J.M.,
D.F.S. and D.E.S. analyzed and interpreted the data. T.D.H.J. wrote the manuscript. T.D.H.J., Z.A.K.,
M.X., F.B.Y., A.J.M., D.F.S., W.W. and D.E.S. reviewed and revised the final manuscript. All authors
have read and agreed to the published version of the manuscript.
Funding: This work was supported by the National Institutes of Health 1R01DK121797-01A1
(T.D.H.J.) and 1R01DK126884-01A1 (D.E.S.), the National Heart, Lung and Blood Institute K01HL125445 (T.D.H.J.) and P01 HL05197-11 (D.E.S.), and the National Institute of General Medical Sciences
P20GM104357-02 (D.E.S.). The lipidomics analysis was supported by COBRE grant (P30 GM127211)
at the University of Kentucky. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.
Institutional Review Board Statement: Animal studies were conducted under the full approval the
University of Mississippi Medical Center’s IACUC in accordance with the NIH Guide for the Care
and Use of Laboratory Animals, protocol number 1283D.
Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are available on request from the
corresponding authors.
Acknowledgments: The authors would like to acknowledge the Analytical and Assay Core in the
Department of Physiology & Biophysics University of Mississippi Medical Center. We also thank
Matthew Hazzard of the University of Kentucky for generating the mouse images used in Figure 1.
Conflicts of Interest: T.D.H.J. and D.E.S. have submitted patents on bilirubin and obesity-related
disorders.

References
1.
2.

3.
4.

5.
6.

7.
8.

9.
10.
11.
12.

Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature
1990, 347, 645–650. [CrossRef]
Gordon, D.M.; Neifer, K.L.; Hamoud, A.A.; Hawk, C.F.; Nestor-Kalinoski, A.L.; Miruzzi, S.A.; Morran, M.P.; Adeosun, S.O.;
Sarver, J.G.; Erhardt, P.W.; et al. Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the
coregulator profile of peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 2020, 295, 9804–9822. [CrossRef] [PubMed]
Gordon, D.M.; Hong, S.H.; Kipp, Z.A.; Hinds, T.D., Jr. Identification of Binding Regions of Bilirubin in the Ligand-Binding Pocket
of the Peroxisome Proliferator-Activated Receptor-A (PPARalpha). Molecules 2021, 26, 2975. [CrossRef]
Gordon, D.M.; Blomquist, T.M.; Miruzzi, S.A.; McCullumsmith, R.; Stec, D.E.; Hinds, T.D., Jr. RNA sequencing in human HepG2
hepatocytes reveals PPAR-alpha mediates transcriptome responsiveness of bilirubin. Physiol. Genom. 2019, 51, 234–240. [CrossRef]
[PubMed]
Stec, D.E.; John, K.; Trabbic, C.J.; Luniwal, A.; Hankins, M.W.; Baum, J.; Hinds, T.D., Jr. Bilirubin Binding to PPARalpha Inhibits
Lipid Accumulation. PLoS ONE 2016, 11, e0153427. [CrossRef] [PubMed]
Srivastava, R.A.; Jahagirdar, R.; Azhar, S.; Sharma, S.; Bisgaier, C.L. Peroxisome proliferator-activated receptor-alpha selective
ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol. Cell.
Biochem. 2006, 285, 35–50. [CrossRef]
Hinds, T.D., Jr.; Creeden, J.F.; Gordon, D.M.; Stec, D.F.; Donald, M.C.; Stec, D.E. Bilirubin Nanoparticles Reduce Diet-Induced
Hepatic Steatosis, Improve Fat Utilization, and Increase Plasma beta-Hydroxybutyrate. Front. Pharm. 2020, 11, 594574. [CrossRef]
Linden, D.; Lindberg, K.; Oscarsson, J.; Claesson, C.; Asp, L.; Li, L.; Gustafsson, M.; Boren, J.; Olofsson, S.O. Influence of
peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo)
B-100 and ApoB-48. J. Biol. Chem. 2002, 277, 23044–23053. [CrossRef]
Shah, A.; Rader, D.J.; Millar, J.S. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010,
210, 35–40. [CrossRef]
Jeong, S.; Yoon, M. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat
diet-induced obese mice. Exp. Mol. Med. 2009, 41, 397–405. [CrossRef]
Yoon, M. PPARalpha in Obesity: Sex Difference and Estrogen Involvement. PPAR Res. 2010, 2010, 584296. [CrossRef] [PubMed]
Tsuchida, A.; Yamauchi, T.; Takekawa, S.; Hada, Y.; Ito, Y.; Maki, T.; Kadowaki, T. Peroxisome proliferator-activated receptor
(PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: Comparison
of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005, 54, 3358–3370. [CrossRef] [PubMed]

Cells 2022, 11, 4

13.

14.

15.
16.

17.

18.
19.

20.

21.

22.

23.

24.

25.
26.

27.

28.
29.
30.

31.

32.
33.

17 of 20

Guerre-Millo, M.; Gervois, P.; Raspe, E.; Madsen, L.; Poulain, P.; Derudas, B.; Herbert, J.M.; Winegar, D.A.; Willson, T.M.; Fruchart,
J.C.; et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol.
Chem. 2000, 275, 16638–16642. [CrossRef]
Lee, S.S.; Pineau, T.; Drago, J.; Lee, E.J.; Owens, J.W.; Kroetz, D.L.; Fernandez-Salguero, P.M.; Westphal, H.; Gonzalez, F.J. Targeted
disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the
pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 1995, 15, 3012–3022. [CrossRef]
Kim, B.H.; Won, Y.S.; Kim, E.Y.; Yoon, M.; Nam, K.T.; Oh, G.T.; Kim, D.Y. Phenotype of peroxisome proliferator-activated
receptor-alpha(PPARalpha)deficient mice on mixed background fed high fat diet. J. Vet. Sci. 2003, 4, 239–244. [CrossRef]
Costet, P.; Legendre, C.; More, J.; Edgar, A.; Galtier, P.; Pineau, T. Peroxisome proliferator-activated receptor alpha-isoform
deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 1998, 273, 29577–29585.
[CrossRef]
Akiyama, T.E.; Nicol, C.J.; Fievet, C.; Staels, B.; Ward, J.M.; Auwerx, J.; Lee, S.S.; Gonzalez, F.J.; Peters, J.M. Peroxisome proliferatoractivated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: Studies with congenic mouse lines. J. Biol.
Chem. 2001, 276, 39088–39093. [CrossRef] [PubMed]
Bougarne, N.; Weyers, B.; Desmet, S.J.; Deckers, J.; Ray, D.W.; Staels, B.; De Bosscher, K. Molecular Actions of PPARalpha in Lipid
Metabolism and Inflammation. Endocr. Rev. 2018, 39, 760–802. [CrossRef] [PubMed]
De Souza, A.T.; Dai, X.; Spencer, A.G.; Reppen, T.; Menzie, A.; Roesch, P.L.; He, Y.; Caguyong, M.J.; Bloomer, S.; Herweijer, H.;
et al. Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice. Nucleic Acids Res. 2006, 34,
4486–4494. [CrossRef]
Hinds, T.D., Jr.; Sodhi, K.; Meadows, C.; Fedorova, L.; Puri, N.; Kim, D.H.; Peterson, S.J.; Shapiro, J.; Abraham, N.G.; Kappas, A.
Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. Obesity 2014,
22, 705–712. [CrossRef]
Stec, D.E.; Gordon, D.M.; Hipp, J.A.; Hong, S.; Mitchell, Z.L.; Franco, N.R.; Robison, J.W.; Anderson, C.D.; Stec, D.F.; Hinds, T.D.,
Jr. The loss of hepatic PPARalpha promotes inflammation and serum hyperlipidemia in diet-induced obesity. Am. J. Physiol.
Regul. Integr. Comp. Physiol. 2019, 317, R733–R745. [CrossRef] [PubMed]
Montagner, A.; Polizzi, A.; Fouche, E.; Ducheix, S.; Lippi, Y.; Lasserre, F.; Barquissau, V.; Regnier, M.; Lukowicz, C.; Benhamed,
F.; et al. Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 2016, 65,
1202–1214. [CrossRef]
Brocker, C.N.; Yue, J.; Kim, D.; Qu, A.; Bonzo, J.A.; Gonzalez, F.J. Hepatocyte-specific PPARA expression exclusively promotes
agonist-induced cell proliferation without influence from nonparenchymal cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2017,
312, G283–G299. [CrossRef] [PubMed]
Wang, X.; Zhu, X.X.; Jiao, S.Y.; Qi, D.; Yu, B.Q.; Xie, G.M.; Liu, Y.; Song, Y.T.; Xu, Q.; Xu, Q.B.; et al. Cardiomyocyte peroxisome
proliferator-activated receptor alpha is essential for energy metabolism and extracellular matrix homeostasis during pressure
overload-induced cardiac remodeling. Acta Pharmacol. Sin. 2021, 1–12. [CrossRef]
Regnier, M.; Polizzi, A.; Smati, S.; Lukowicz, C.; Fougerat, A.; Lippi, Y.; Fouche, E.; Lasserre, F.; Naylies, C.; Betoulieres, C.; et al.
Hepatocyte-specific deletion of Pparalpha promotes NAFLD in the context of obesity. Sci. Rep. 2020, 10, 6489. [CrossRef]
Gordon, D.M.; Adeosun, S.O.; Ngwudike, S.I.; Anderson, C.D.; Hall, J.E.; Hinds, T.D., Jr.; Stec, D.E. CRISPR Cas9-mediated
deletion of biliverdin reductase A (BVRA) in mouse liver cells induces oxidative stress and lipid accumulation. Arch. Biochem.
Biophys. 2019, 672, 108072. [CrossRef]
Hinds, T.D., Jr.; Hosick, P.A.; Hankins, M.W.; Nestor-Kalinoski, A.; Stec, D.E. Mice with hyperbilirubinemia due to Gilbert’s
Syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARalpha. Am. J. Physiol.
Endocrinol. Metab. 2017, 312, E244–E252. [CrossRef]
Hinds, T.D., Jr.; Adeosun, S.O.; Alamodi, A.A.; Stec, D.E. Does bilirubin prevent hepatic steatosis through activation of the
PPARalpha nuclear receptor? Med. Hypotheses 2016, 95, 54–57. [CrossRef]
Creeden, J.F.; Gordon, D.M.; Stec, D.E.; Hinds, T.D., Jr. Bilirubin as a metabolic hormone: The physiological relevance of low
levels. Am. J. Physiol. Endocrinol. Metab. 2021, 320, E191–E207. [CrossRef]
Hinds, T.D., Jr.; Burns, K.A.; Hosick, P.A.; McBeth, L.; Nestor-Kalinoski, A.; Drummond, H.A.; AlAmodi, A.A.; Hankins, M.W.;
Vanden Heuvel, J.P.; Stec, D.E. Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase
(GSK) 3beta phosphorylation of serine 73 of peroxisome proliferator-activated receptor (PPAR) alpha. J. Biol. Chem. 2016, 291,
25179–25191. [CrossRef]
Mueller, P.A.; Yang, L.; Ubele, M.; Mao, G.; Brandon, J.; Vandra, J.; Nichols, T.C.; Escalante-Alcalde, D.; Morris, A.J.; Smyth, S.S.
Coronary Artery Disease Risk-Associated Plpp3 Gene and Its Product Lipid Phosphate Phosphatase 3 Regulate Experimental
Atherosclerosis. Arter. Thromb. Vasc. Biol. 2019, 39, 2261–2272. [CrossRef] [PubMed]
Kraemer, M.P.; Mao, G.; Hammill, C.; Yan, B.; Li, Y.; Onono, F.; Smyth, S.S.; Morris, A.J. Effects of diet and hyperlipidemia on
levels and distribution of circulating lysophosphatidic acid. J. Lipid Res. 2019, 60, 1818–1828. [CrossRef]
Khan, M.J.; Codreanu, S.G.; Goyal, S.; Wages, P.A.; Gorti, S.K.K.; Pearson, M.J.; Uribe, I.; Sherrod, S.D.; McLean, J.A.; Porter, N.A.;
et al. Evaluating a targeted multiple reaction monitoring approach to global untargeted lipidomic analyses of human plasma.
Rapid Commun. Mass Spectrom. 2020, 34, e8911. [CrossRef]

Cells 2022, 11, 4

34.

35.

36.

37.
38.

39.
40.
41.
42.

43.
44.
45.

46.
47.
48.
49.
50.

51.

52.
53.
54.
55.
56.
57.
58.
59.

18 of 20

Marino, J.S.; Stechschulte, L.A.; Stec, D.E.; Nestor-Kalinoski, A.; Coleman, S.; Hinds, T.D., Jr. Glucocorticoid receptor beta induces
hepatic steatosis by augmenting inflammation and inhibition of the peroxisome proliferator-activated receptor (PPAR) alpha. J.
Biol. Chem. 2016, 291, 25776–25788. [CrossRef] [PubMed]
Hinds, T.D., Jr.; Stechschulte, L.A.; Cash, H.A.; Whisler, D.; Banerjee, A.; Yong, W.; Khuder, S.S.; Kaw, M.K.; Shou, W.; Najjar, S.M.;
et al. Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome
proliferator-activated receptor-gamma (PPARgamma). J. Biol. Chem. 2011, 286, 42911–42922. [CrossRef]
Stec, D.E.; Gordon, D.M.; Nestor-Kalinoski, A.L.; Donald, M.C.; Mitchell, Z.L.; Creeden, J.F.; Hinds, T.D., Jr. Biliverdin Reductase
A (BVRA) Knockout in Adipocytes Induces Hypertrophy and Reduces Mitochondria in White Fat of Obese Mice. Biomolecules
2020, 10, 387. [CrossRef]
Shen, Y.; Su, Y.; Silva, F.J.; Weller, A.H.; Sostre-Colon, J.; Titchenell, P.M.; Steger, D.J.; Seale, P.; Soccio, R.E. Shared PPARalpha/gamma Target Genes Regulate Brown Adipocyte Thermogenic Function. Cell Rep. 2020, 30, 3079–3091.e5. [CrossRef]
Goto, T.; Lee, J.Y.; Teraminami, A.; Kim, Y.I.; Hirai, S.; Uemura, T.; Inoue, H.; Takahashi, N.; Kawada, T. Activation of peroxisome
proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes. J. Lipid Res. 2011, 52,
873–884. [CrossRef] [PubMed]
Jeong, S.; Yoon, M. Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen. Obesity
2007, 15, 1430–1440. [CrossRef] [PubMed]
Yoon, M. The role of PPARalpha in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARalpha actions.
Pharmacol. Res. 2009, 60, 151–159. [CrossRef]
Lee, H.; Yoon, M. 17β-estradiol inhibits PPARα of skeletal muscle. Anim. Cells Syst. 2013, 17, 331–340. [CrossRef]
Wang, Y.; Shoemaker, R.; Thatcher, S.E.; Batifoulier-Yiannikouris, F.; English, V.L.; Cassis, L.A. Administration of 17beta-estradiol
to ovariectomized obese female mice reverses obesity-hypertension through an ACE2-dependent mechanism. Am. J. Physiol.
Endocrinol. Metab. 2015, 308, E1066–E1075. [CrossRef] [PubMed]
Kersten, S.; Seydoux, J.; Peters, J.M.; Gonzalez, F.J.; Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptor alpha
mediates the adaptive response to fasting. J. Clin. Investig. 1999, 103, 1489–1498. [CrossRef]
Grabacka, M.; Pierzchalska, M.; Dean, M.; Reiss, K. Regulation of Ketone Body Metabolism and the Role of PPARalpha. Int. J.
Mol. Sci. 2016, 17, 2093. [CrossRef]
Hopkins, T.A.; Sugden, M.C.; Holness, M.J.; Kozak, R.; Dyck, J.R.; Lopaschuk, G.D. Control of cardiac pyruvate dehydrogenase
activity in peroxisome proliferator-activated receptor-alpha transgenic mice. Am. J. Physiol. Heart Circ. Physiol. 2003, 285,
H270–H276. [CrossRef] [PubMed]
Krause, B.R.; Hartman, A.D. Adipose tissue and cholesterol metabolism. J. Lipid Res. 1984, 25, 97–110. [CrossRef]
Goldstein, J.L.; Brown, M.S. A century of cholesterol and coronaries: From plaques to genes to statins. Cell 2015, 161, 161–172.
[CrossRef] [PubMed]
Sekiya, M.; Yahagi, N.; Matsuzaka, T.; Takeuchi, Y.; Nakagawa, Y.; Takahashi, H.; Okazaki, H.; Iizuka, Y.; Ohashi, K.; Gotoda, T.;
et al. SREBP-1-independent regulation of lipogenic gene expression in adipocytes. J. Lipid Res. 2007, 48, 1581–1591. [CrossRef]
Wu, X.; Romero, D.; Swiatek, W.I.; Dorweiler, I.; Kikani, C.K.; Sabic, H.; Zweifel, B.S.; McKearn, J.; Blitzer, J.T.; Nickols, G.A.; et al.
PAS kinase drives lipogenesis through SREBP-1 maturation. Cell Rep. 2014, 8, 242–255. [CrossRef]
Ebke, L.A.; Nestor-Kalinoski, A.L.; Slotterbeck, B.D.; Al-Dieri, A.G.; Ghosh-Lester, S.; Russo, L.; Najjar, S.M.; von Grafenstein,
H.; McInerney, M.F. Tight association between macrophages and adipocytes in obesity: Implications for adipocyte preparation.
Obesity 2014, 22, 1246–1255. [CrossRef]
Zhang, F.; Hao, G.; Shao, M.; Nham, K.; An, Y.; Wang, Q.; Zhu, Y.; Kusminski, C.M.; Hassan, G.; Gupta, R.K.; et al. An Adipose
Tissue Atlas: An Image-Guided Identification of Human-like BAT and Beige Depots in Rodents. Cell Metab. 2018, 27, 252–262.e3.
[CrossRef] [PubMed]
MacCannell, A.D.V.; Futers, T.S.; Whitehead, A.; Moran, A.; Witte, K.K.; Roberts, L.D. Sexual dimorphism in adipose tissue
mitochondrial function and metabolic flexibility in obesity. Int. J. Obes. 2021, 45, 1773–1781. [CrossRef]
Chait, A.; den Hartigh, L.J. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and
Cardiovascular Disease. Front. Cardiovasc. Med. 2020, 7, 22. [CrossRef] [PubMed]
Sam, S. Differential effect of subcutaneous abdominal and visceral adipose tissue on cardiometabolic risk. Horm. Mol. Biol. Clin.
Investig. 2018, 33, 20180014. [CrossRef]
O’Brien, L.; Hosick, P.A.; John, K.; Stec, D.E.; Hinds, T.D., Jr. Biliverdin reductase isozymes in metabolism. Trends Endocrinol.
Metab. 2015, 26, 212–220. [CrossRef]
John, K.; Marino, J.S.; Sanchez, E.R.; Hinds, T.D., Jr. The glucocorticoid receptor: Cause of or cure for obesity? Am. J. Physiol.
Endocrinol. Metab. 2016, 310, E249–E257. [CrossRef] [PubMed]
Yu, B.L.; Zhao, S.P.; Hu, J.R. Cholesterol imbalance in adipocytes: A possible mechanism of adipocytes dysfunction in obesity.
Obes. Rev. Off. J. Int. Assoc. Study Obes. 2010, 11, 560–567. [CrossRef]
la Rose, A.M.; Bazioti, V.; Westerterp, M. Adipocyte Membrane Cholesterol Regulates Obesity. Arter. Thromb. Vasc. Biol. 2018, 38,
687–689. [CrossRef]
Saraswathi, V.; Gao, L.; Morrow, J.D.; Chait, A.; Niswender, K.D.; Hasty, A.H. Fish oil increases cholesterol storage in white
adipose tissue with concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in mice. J. Nutr. 2007, 137,
1776–1782. [CrossRef] [PubMed]

Cells 2022, 11, 4

60.
61.
62.
63.
64.
65.

66.
67.

68.
69.
70.

71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.

84.
85.

86.

19 of 20

Chui, P.C.; Guan, H.P.; Lehrke, M.; Lazar, M.A. PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL
receptor 1. J. Clin. Investig. 2005, 115, 2244–2256. [CrossRef]
Chinetti, G.; Lestavel, S.; Fruchart, J.C.; Clavey, V.; Staels, B. Peroxisome proliferator-activated receptor alpha reduces cholesterol
esterification in macrophages. Circ. Res. 2003, 92, 212–217. [CrossRef] [PubMed]
Smedlund, K.B.; Sanchez, E.R.; Hinds, T.D., Jr. FKBP51 and the molecular chaperoning of metabolism. Trends Endocrinol. Metab.
2021, 32, 862–874. [CrossRef]
Chiu, M.; McBeth, L.; Sindhwani, P.; Hinds, T.D. Deciphering the Roles of Thiazolidinediones and PPARgamma in Bladder
Cancer. PPAR Res. 2017, 2017, 4810672. [CrossRef]
Kim, J.B.; Spiegelman, B.M. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid
metabolism. Genes Dev. 1996, 10, 1096–1107. [CrossRef] [PubMed]
Crewe, C.; Zhu, Y.; Paschoal, V.A.; Joffin, N.; Ghaben, A.L.; Gordillo, R.; Oh, D.Y.; Liang, G.; Horton, J.D.; Scherer, P.E. SREBPregulated adipocyte lipogenesis is dependent on substrate availability and redox modulation of mTORC1. JCI Insight 2019, 5,
e129397. [CrossRef]
Miyazaki, M.; Kim, Y.C.; Gray-Keller, M.P.; Attie, A.D.; Ntambi, J.M. The biosynthesis of hepatic cholesterol esters and triglycerides
is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J. Biol. Chem. 2000, 275, 30132–30138. [CrossRef]
Ntambi, J.M.; Miyazaki, M.; Stoehr, J.P.; Lan, H.; Kendziorski, C.M.; Yandell, B.S.; Song, Y.; Cohen, P.; Friedman, J.M.; Attie, A.D.
Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl. Acad. Sci. USA 2002, 99, 11482–11486.
[CrossRef] [PubMed]
Dongil, P.; Perez-Garcia, A.; Hurtado-Carneiro, V.; Herrero-de-Dios, C.; Blazquez, E.; Alvarez, E.; Sanz, C. Pas Kinase Deficiency
Triggers Antioxidant Mechanisms in the Liver. Sci. Rep. 2018, 8, 13810. [CrossRef]
Adeosun, S.O.; Moore, K.H.; Lang, D.M.; Nwaneri, A.C.; Hinds, T.D., Jr.; Stec, D.E. A Novel Fluorescence-Based Assay for the
Measurement of Biliverdin Reductase Activity. React. Oxyg. Species 2018, 5, 35–45. [CrossRef]
Adeosun, S.O.; Gordon, D.M.; Weeks, M.F.; Moore, K.H.; Hall, J.E.; Hinds, T.D., Jr.; Stec, D.E. Loss of biliverdin reductase-A
promotes lipid accumulation and lipotoxicity in mouse proximal tubule cells. Am. J. Physiol. Ren. Physiol. 2018, 315, F323–F331.
[CrossRef]
Dongil, P.; Perez-Garcia, A.; Hurtado-Carneiro, V.; Herrero-de-Dios, C.; Alvarez, E.; Sanz, C. PAS kinase deficiency reduces aging
effects in mice. Aging 2020, 12, 2275–2301. [CrossRef]
Perez-Garcia, A.; Dongil, P.; Hurtado-Carneiro, V.; Blazquez, E.; Sanz, C.; Alvarez, E. PAS Kinase deficiency alters the glucokinase
function and hepatic metabolism. Sci. Rep. 2018, 8, 11091. [CrossRef]
Perez-Garcia, A.; Dongil, P.; Hurtado-Carneiro, V.; Blazquez, E.; Sanz, C.; Alvarez, E. High-fat diet alters PAS kinase regulation by
fasting and feeding in liver. J. Nutr. Biochem. 2018, 57, 14–25. [CrossRef] [PubMed]
Hao, H.X.; Cardon, C.M.; Swiatek, W.; Cooksey, R.C.; Smith, T.L.; Wilde, J.; Boudina, S.; Abel, E.D.; McClain, D.A.; Rutter, J. PAS
kinase is required for normal cellular energy balance. Proc. Natl. Acad. Sci. USA 2007, 104, 15466–15471. [CrossRef]
Zhang, D.D.; Zhang, J.G.; Wang, Y.Z.; Liu, Y.; Liu, G.L.; Li, X.Y. Per-Arnt-Sim Kinase (PASK): An Emerging Regulator of
Mammalian Glucose and Lipid Metabolism. Nutrients 2015, 7, 7437–7450. [CrossRef]
Grabacka, M.; Reiss, K. Anticancer Properties of PPARalpha-Effects on Cellular Metabolism and Inflammation. PPAR Res. 2008,
2008, 930705. [CrossRef] [PubMed]
Stec, D.E.; Hinds, T.D., Jr. Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease. Int. J.
Mol. Sci. 2020, 21, 9493. [CrossRef]
Hinds, T.D., Jr.; Stec, D.E. Bilirubin Safeguards Cardiorenal and Metabolic Diseases: A Protective Role in Health. Curr. Hypertens.
Rep. 2019, 21, 87. [CrossRef] [PubMed]
Weaver, L.; Hamoud, A.R.; Stec, D.E.; Hinds, T.D., Jr. Biliverdin reductase and bilirubin in hepatic disease. Am. J. Physiol.
Gastrointest. Liver Physiol. 2018, 314, G668–G676. [CrossRef]
Sundararaghavan, V.L.; Binepal, S.; Stec, D.E.; Sindhwani, P.; Hinds, T.D., Jr. Bilirubin, a new therapeutic for kidney transplant?
Transpl. Rev. 2018, 32, 234–240. [CrossRef]
Hinds, T.D., Jr.; Stec, D.E. Bilirubin, a Cardiometabolic Signaling Molecule. Hypertension 2018, 72, 788–795. [CrossRef]
Hamoud, A.R.; Weaver, L.; Stec, D.E.; Hinds, T.D., Jr. Bilirubin in the Liver-Gut Signaling Axis. Trends Endocrinol. Metab. 2018, 29,
140–150. [CrossRef] [PubMed]
Hinds, T.D., Jr.; Creeden, J.F.; Gordon, D.M.; Spegele, A.C.; Britton, S.L.; Koch, L.G.; Stec, D.E. Rats Genetically Selected for High
Aerobic Exercise Capacity Have Elevated Plasma Bilirubin by Upregulation of Hepatic Biliverdin Reductase-A (BVRA) and
Suppression of UGT1A1. Antioxidants 2020, 9, 889. [CrossRef]
Lumeng, C.N.; Bodzin, J.L.; Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin.
Invest. 2007, 117, 175–184. [CrossRef] [PubMed]
Becerril, S.; Rodriguez, A.; Catalan, V.; Mendez-Gimenez, L.; Ramirez, B.; Sainz, N.; Llorente, M.; Unamuno, X.; Gomez-Ambrosi,
J.; Fruhbeck, G. Targeted disruption of the iNOS gene improves adipose tissue inflammation and fibrosis in leptin-deficient ob/ob
mice: Role of tenascin C. Int. J. Obes. 2018, 42, 1458–1470. [CrossRef]
Hinds, T.D.; Peck, B.; Shek, E.; Stroup, S.; Hinson, J.; Arthur, S.; Marino, J.S. Overexpression of Glucocorticoid Receptor beta
Enhances Myogenesis and Reduces Catabolic Gene Expression. Int. J. Mol. Sci. 2016, 17, 232. [CrossRef] [PubMed]

Cells 2022, 11, 4

87.
88.
89.
90.
91.

20 of 20

Hinds, T.D., Jr.; Ramakrishnan, S.; Cash, H.A.; Stechschulte, L.A.; Heinrich, G.; Najjar, S.M.; Sanchez, E.R. Discovery of
glucocorticoid receptor-beta in mice with a role in metabolism. Mol. Endocrinol. 2010, 24, 1715–1727. [CrossRef] [PubMed]
Stechschulte, L.A.; Wuescher, L.; Marino, J.S.; Hill, J.W.; Eng, C.; Hinds, T.D., Jr. Glucocorticoid receptor beta stimulates Akt1
growth pathway by attenuation of PTEN. J. Biol. Chem. 2014, 289, 17885–17894. [CrossRef]
McBeth, L.; Nwaneri, A.C.; Grabnar, M.; Demeter, J.; Nestor-Kalinoski, A.; Hinds, T.D., Jr. Glucocorticoid receptor beta increases
migration of human bladder cancer cells. Oncotarget 2016, 7, 27313–27324. [CrossRef]
McBeth, L.; Grabnar, M.; Selman, S.; Hinds, T.D., Jr. Involvement of the Androgen and Glucocorticoid Receptors in Bladder
Cancer. Int. J. Endocrinol. 2015, 2015, 384860. [CrossRef]
Nguyen, Q.T.; Kim, D.; Iamsawat, S.; Le, H.T.; Kim, S.; Qiu, K.T.; Hinds, T.D.; Bazeley, P.; O’Shea, J.J.; Choi, J.; et al. Cutting Edge:
Steroid Responsiveness in Foxp3(+) Regulatory T Cells Determines Steroid Sensitivity during Allergic Airway Inflammation in
Mice. J. Immunol. 2021, 207, 765–770. [CrossRef] [PubMed]

